贝罗司他胶囊(berotralstat)，有效预防遗传性血管水肿发作

The U.S. Food and Drug Administration (FDA) has approved Orladeyo (Chinese translation:) capsules, a once-daily oral medication for the prevention of hereditary angioedema (HAE) attacks in children and adults aged ≥12 years. It is worth mentioning that Orladeyo is the first targeted oral therapy approved to prevent HAE attacks. The approval of the drug will bring significant progress in the treatment of HAE patients and help reduce the treatment burden on patients.

Oradejo is a plasma kallikrein inhibitor that binds to plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high molecular weight kininogen (HMWK) to produce cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability, leading to the association with HAE Associated Swelling In patients with HAE due to C1 inhibitor (C1-INH) deficiency or dysfunction, plasma kallikrein activity is not regulated normally, which leads to an uncontrolled increase in plasma kallikrein activity and leads to angioedema attack. Oladidate reduces plasma kallikrein activity to control excessive bradykinin production in hospitalized patients with HAE.

Recommended dose of Berostat: Take one capsule (150 mg) once daily with food. Taking more than one Orladeyo capsule a day may cause heart rhythm problems with QT prolongation, a condition that causes an abnormal heartbeat. The most common adverse reactions (≥10%) were abdominal pain, vomiting, diarrhea, back pain, and gastroesophageal reflux disease. Less common side effects include: Abnormal liver function tests. Less common side effects: Brief, itchy rash. If serious adverse reactions occur during medication, you must contact your doctor promptly to determine the subsequent treatment plan.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.